» Articles » PMID: 32258481

A Perspective on Research, Diagnosis, and Management of Lysosomal Storage Disorders in Colombia

Abstract

Lysosomal storage diseases (LSDs) are a group of about 50 inborn errors of metabolism characterized by the lysosomal accumulation of partially or non-degraded molecules due to mutations in proteins involved in the degradation of macromolecules, transport, lysosomal biogenesis or modulators of lysosomal environment. Significant advances have been achieved in the diagnosis, management, and treatment of LSDs patients. In terms of approved therapies, these include enzyme replacement therapy (ERT), substrate reduction therapy, hematopoietic stem cell transplantation, and pharmacological chaperone therapy. In this review, we summarize the Colombian experience in LSDs thorough the evidence published. We identified 113 articles published between 1995 and 2019 that included Colombian researchers or physicians, and which were mainly focused in Mucopolysaccharidoses, Pompe disease, Gaucher disease, Fabry disease, and Tay-Sachs and Sandhoff diseases. Most of these articles focused on basic research, clinical cases, and mutation reports. Noteworthy, implementation of the enzyme assay in dried blood samples, led to a 5-fold increase in the identification of LSD patients, suggesting that these disorders still remain undiagnosed in the country. We consider that the information presented in this review will contribute to the knowledge of a broad spectrum of LSDs in Colombia and will also contribute to the development of public policies and the identification of research opportunities.

Citing Articles

A kaleidoscopic view of extracellular vesicles in lysosomal storage disorders.

Hegeman C, de Jong O, Lorenowicz M Extracell Vesicles Circ Nucl Acids. 2024; 3(4):393-421.

PMID: 39697359 PMC: 11651879. DOI: 10.20517/evcna.2022.41.


Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020-2023).

Therrell B, Padilla C, Borrajo G, Khneisser I, Schielen P, Knight-Madden J Int J Neonatal Screen. 2024; 10(2).

PMID: 38920845 PMC: 11203842. DOI: 10.3390/ijns10020038.


Evidence of epigenetic landscape shifts in mucopolysaccharidosis IIIB and IVA.

Vargas-Lopez V, Prada L, Almeciga-Diaz C Sci Rep. 2024; 14(1):3961.

PMID: 38368436 PMC: 10874391. DOI: 10.1038/s41598-024-54626-4.


Efficient CRISPR/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA.

Leal A, Almeciga-Diaz C Gene Ther. 2022; 30(1-2):107-114.

PMID: 35581402 DOI: 10.1038/s41434-022-00344-3.


Design and Validation of a Custom NGS Panel Targeting a Set of Lysosomal Storage Diseases Candidate for NBS Applications.

La Cognata V, Guarnaccia M, Morello G, Ruggieri M, Polizzi A, Cavallaro S Int J Mol Sci. 2021; 22(18).

PMID: 34576242 PMC: 8470217. DOI: 10.3390/ijms221810064.


References
1.
McCafferty E, Scott L . Vestronidase Alfa: A Review in Mucopolysaccharidosis VII. BioDrugs. 2019; 33(2):233-240. PMC: 6469592. DOI: 10.1007/s40259-019-00344-7. View

2.
Prada C, Gonzaga-Jauregui C, Tannenbaum R, Penney S, Lupski J, Hopkin R . Clinical utility of whole-exome sequencing in rare diseases: Galactosialidosis. Eur J Med Genet. 2014; 57(7):339-344. PMC: 4065856. DOI: 10.1016/j.ejmg.2014.04.005. View

3.
Ohashi T . Gene therapy for lysosomal storage diseases and peroxisomal diseases. J Hum Genet. 2018; 64(2):139-143. DOI: 10.1038/s10038-018-0537-5. View

4.
Almeciga-Diaz C, Rueda-Paramo M, Espejo A, Echeverri O, Montano A, Tomatsu S . Effect of elongation factor 1alpha promoter and SUMF1 over in vitro expression of N-acetylgalactosamine-6-sulfate sulfatase. Mol Biol Rep. 2008; 36(7):1863-70. DOI: 10.1007/s11033-008-9392-3. View

5.
Almeciga-Diaz C, Hidalgo O, Olarte-Avellaneda S, Rodriguez-Lopez A, Guzman E, Garzon R . Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA. J Med Chem. 2019; 62(13):6175-6189. PMC: 11292729. DOI: 10.1021/acs.jmedchem.9b00428. View